Modeling The Cost-Effectiveness of The All Oral, Direct-Acting Antiviral Regimen Daclatasvir Plus Sofosbuvir In Patients Co-Infected With Hepatitis C Virus (Hcv) And Hiv
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.2213
https://www.valueinhealthjournal.com/article/S1098-3015(15)04289-8/fulltext
Title :
Modeling The Cost-Effectiveness of The All Oral, Direct-Acting Antiviral Regimen Daclatasvir Plus Sofosbuvir In Patients Co-Infected With Hepatitis C Virus (Hcv) And Hiv
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04289-8&doi=10.1016/j.jval.2015.09.2213
First page :
A628
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
1631